88 research outputs found
Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus
BACKGROUND: Diabetic nephropathy is a serious complication of diabetes mellitus and is associated with considerable morbidity and high mortality. There is increasing evidence to suggest that dysregulation of the epigenome is involved in diabetic nephropathy. We assessed whether epigenetic modification of DNA methylation is associated with diabetic nephropathy in a case-control study of 192 Irish patients with type 1 diabetes mellitus (T1D). Cases had T1D and nephropathy whereas controls had T1D but no evidence of renal disease. METHODS: We performed DNA methylation profiling in bisulphite converted DNA from cases and controls using the recently developed Illumina Infinium(R) HumanMethylation27 BeadChip, that enables the direct investigation of 27,578 individual cytosines at CpG loci throughout the genome, which are focused on the promoter regions of 14,495 genes. RESULTS: Singular Value Decomposition (SVD) analysis indicated that significant components of DNA methylation variation correlated with patient age, time to onset of diabetic nephropathy, and sex. Adjusting for confounding factors using multivariate Cox-regression analyses, and with a false discovery rate (FDR) of 0.05, we observed 19 CpG sites that demonstrated correlations with time to development of diabetic nephropathy. Of note, this included one CpG site located 18 bp upstream of the transcription start site of UNC13B, a gene in which the first intronic SNP rs13293564 has recently been reported to be associated with diabetic nephropathy. CONCLUSION: This high throughput platform was able to successfully interrogate the methylation state of individual cytosines and identified 19 prospective CpG sites associated with risk of diabetic nephropathy. These differences in DNA methylation are worthy of further follow-up in replication studies using larger cohorts of diabetic patients with and without nephropathy
Determinants of the development of diabetes (maturity-onset diabetes of the young-3) in carriers of HNF-1a mutations. Evidence for parent-of-origin effect
WSTĘP. Celem pracy była ocena rozkładu wieku badanych w chwili
wystąpienia cukrzycy typu MODY 3 (maturity-onset diabetes of the young-3)
oraz określenie czynników determinujących ujawnienie się cukrzycy u nosicieli
mutacji HNF-1a.
MATERIAŁ I METODY. Przebadano rodziny (n = 104) z cukrzycą typu
2 dziedziczoną dominująco, pod kątem występowania wywołującej ją mutacji HNF-1a.
WYNIKI. Mutacje HNF-1a współistniały
z cukrzycą tylko w 13 rodzinach; we wszystkich przypadkach średni wiek chorych
w chwili wystąpienia cukrzycy wynosił poniżej 35 lat. Obserwowano brak lub zmniejszenie
wydzielania insuliny u nosicieli mutacji (n = 101). Do rozwoju cukrzycy doszło
u 65% badanych w wieku do 25 lat, a u 100% do czasu ukończenia 50 lat. Jeśli cukrzyca
była dziedziczona po matce, występowała w bardzo młodym wieku, zwłaszcza u osób, które zostały poddane ekspozycji na tę chorobę już w środowisku wewnątrzmacicznym;
u 57 ± 8% cukrzyca ujawniła się do 15 roku życia, w porównaniu z 0,0% u osób niepoddanych
tej ekspozycji (p < 7 × 10-6). U osób w wieku 25 lat różnica ta uległa zmniejszeniu
(odpowiednio 85 ± 6 i 55 ± 12%; p = 0,02). Jeśli mutację odziedziczono po ojcu,
cukrzyca rozwijała się u 52 ± 8% do czasu ukończenia 25 lat. Okazało się, że wiek w chwili rozpoznania jest dziedziczny (h2 = 0,47; p = 0,003). Po uwzględnieniu
w analizie faktu, który z rodziców przekazał mutację, zakres udziału czynników
genetycznych znacznie się zwiększał (h2 = 0,91).
WNIOSKI. Mutacje HNF-1a odpowiadają
za rozwój cukrzycy w niewielkim odsetku rodzin z dominującym sposobem dziedziczenia.
Wiek w chwili rozwoju cukrzycy był znacznie zróżnicowany w poszczególnych rodzinach
z MODY 3 i podlegał wpływowi czynników rodzinnych (łącznie z genami modyfikującymi)
oraz zależał od rodzica, przekazującego mutację (czy nosiciel mutacji podlegał
ekspozycji na cukrzycę w środowisku wewnątrzmacicznym).INTRODUCTION. To determine the distribution of the
age at onset of diabetes (maturity-onset diabetes of the young-3 [MODY 3]and to identify determinants
of the onset of diabetes in carriers of HNF-1a
mutations.
MATERIAL AND METHODS. Extended families (n = 104)
with type 2 diabetes inherited in a dominant pattern
were recruited and screened for diabetes-causing
mutations in HNF-1a.
RESULTS. HNF-1a mutations cosegregated with diabetes
in only 13 families, all with a mean age at onset
< 35 years. Insulin secretion was diminished or
absent in mutation carriers (n = 101), and diabetes
developed in 65% by age 25 years and in 100% by
age 50 years. If the mutation was inherited from
the mother, diabetes onset was very young in those
exposed to diabetes in utero; 57 ± 8% were affected
by age 15 years as compared with 0,0% in those
not exposed (p < 7 × 10–6). By age 25 years, the difference
was reduced (85 ± 6 and 55 ± 12%, respectively;
P = 0.02). If the mutation was inherited from
the father, diabetes developed in 52 ± 8% by age
25 years. Age at diagnosis was shown to be highly
heritable (h2 = 0.47, P = 0.003). When parent of origin
was included in the analyses, the magnitude of
genetic contribution increased markedly (h2 = 0.91).
CONCLUSIONS. Mutations in HNF-1a accounts for
diabetes in a small proportion of families with
a dominant pattern of inheritance. Age at onset of
diabetes in MODY 3 families varied widely and was
influenced by familial factors (including modifying
genes) and parent of origin (whether a mutation
carrier was exposed to diabetes in utero)
Rs1888747 polymorphism in the FRMD3 gene, gene and protein expression: Role in diabetic kidney disease
© 2016 Buffon et al. Background: We carried out a case-control study in patients with type 2 diabetes mellitus (T2DM) to evaluate the association between seven single nucleotide polymorphisms (SNPs) previously described to be linked to diabetic kidney disease (DKD) in type 1 diabetes mellitus (T1DM). Additionally, we evaluated gene and protein expression related to the polymorphism associated with DKD. Methods: The association study included 1098 T2DM patients (718 with DKD and 380 without DKD). Out of the 13 polymorphisms associated with DKD in a previous study with T1DM, seven were chosen for evaluation in this sample: rs1888747, rs9521445, rs39075, rs451041, rs1041466, rs1411766 and rs6492208. The expression study included 91 patients who underwent nephrectomy. Gene expression was assessed by RT-qPCR and protein expression in kidney samples was quantified by western blot and it localization by immunohistochemistry. Results: The C/C genotype of rs1888747 SNP was associated with protection for DKD (OR = 0.6, 95 % CI 0.3-0.9; P = 0.022). None of the other SNPs were associated with DKD. rs1888747 is located near FRMD3 gene. Therefore, FRMD3 gene and protein expression were evaluated in human kidney tissue according to rs1888747 genotypes. Gene and protein expression were similar in subjects homozygous for the C allele and in those carrying the G allele. Conclusions: Replication of the association between rs1888747 SNP and DKD in a different population suggests that this link is not the result of chance. rs1888747 SNP is located at the FRMD3 gene, which is expressed in human kidney. Therefore, this gene is a candidate gene for DKD. However, in this study, no rs1888747 genotype or specific allele effect on gene and/or protein expression of the FRMD3 gene was demonstrated
Recommended from our members
Genome-Wide Association Scan for Diabetic Nephropathy Susceptibility Genes in Type 1 Diabetes
OBJECTIVE—Despite extensive evidence for genetic susceptibility
to diabetic nephropathy, the identification of susceptibility
genes and their variants has had limited success. To search for
genes that contribute to diabetic nephropathy, a genome-wide
association scan was implemented on the Genetics of Kidneys in
Diabetes collection.
RESEARCH DESIGN AND METHODS—We genotyped
360,000 single nucleotide polymorphisms (SNPs) in 820 case
subjects (284 with proteinuria and 536 with end-stage renal
disease) and 885 control subjects with type 1 diabetes. Confirmation
of implicated SNPs was sought in 1,304 participants of the
Diabetes Control and Complications Trial (DCCT)/Epidemiology
of Diabetes Interventions and Complications (EDIC) study, a
long-term, prospective investigation of the development of diabetes-
associated complications.
RESULTS—A total of 13 SNPs located in four genomic loci were
associated with diabetic nephropathy with P1105. The
strongest association was at the FRMD3 (4.1 protein ezrin,
radixin, moesin [FERM] domain containing 3) locus (odds ratio
[OR]1.45, P5.0107). A strong association was also
identified at the CARS (cysteinyl-tRNA synthetase) locus (OR
1.36, P3.1106). Associations between both loci and time to
onset of diabetic nephropathy were supported in the DCCT/EDIC
study (hazard ratio [HR]1.33, P0.02, and HR1.32, P
0.01, respectively). We demonstrated expression of both FRMD3
and CARS in human kidney.
CONCLUSIONS—We identified genetic associations for susceptibility
to diabetic nephropathy at two novel candidate loci near
the FRMD3 and CARS genes. Their identification implicates
previously unsuspected pathways in the pathogenesis of this
important late complication of type 1 diabetes
Different molecular patterns in glioblastoma multiforme subtypes upon recurrence
One of the hallmarks of glioblastoma is its inherent tendency to recur. At this point patients with relapsed GBM show a survival time of only few months. The molecular basis of the recurrence process in GBM is still poorly understood. The aim of the present study was to investigate the genetic profile of relapsed GBM compared to their respective primary tumors. We have included 20 paired GBMs. In all tumor samples, we have analyzed p53 and PTEN status by sequencing analysis, EGFR amplification by semiquantitative PCR and a wide-genome fingerprinting was performed by microsatellite analysis. Among primary GBM, we observed twelve type 2 GBM, four type 1 GBM and four further GBM showing neither p53 mutations nor EGFR amplification (non-type 1–non-type 2 GBM). Upon recurrence, we have detected two molecular patterns of tumor progression: GBM initially showing either type 1 or type 2 profiles conserved them at the time of relapse. In contrast, non-type 1–non-type 2 GBM acquired the typical pattern of type 2 GBM and harbor EGFR amplification without p53 mutation. New PTEN mutations upon relapse were only detected in type 2 GBM. Additional LOH were more frequently identified in relapses of type 2 GBM than in those showing the type 1 signature. Taken together, our results strongly suggest that recurrences of GBM may display two distinct pattern of accumulation of molecular alterations depending on the profile of the original tumor
High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients
Approximately 25% of all patients with stage II colorectal cancer will experience recurrent disease and subsequently die within 5 years. MicroRNA-21 (miR-21) is upregulated in several cancer types and has been associated with survival in colon cancer. In the present study we developed a robust in situ hybridization assay using high-affinity Locked Nucleic Acid (LNA) probes that specifically detect miR-21 in formalin-fixed paraffin embedded (FFPE) tissue samples. The expression of miR-21 was analyzed by in situ hybridization on 130 stage II colon and 67 stage II rectal cancer specimens. The miR-21 signal was revealed as a blue chromogenic reaction, predominantly observed in fibroblast-like cells located in the stromal compartment of the tumors. The expression levels were measured using image analysis. The miR-21 signal was determined as the total blue area (TB), or the area fraction relative to the nuclear density (TBR) obtained using a red nuclear stain. High TBR (and TB) estimates of miR-21 expression correlated significantly with shorter disease-free survival (p = 0.004, HR = 1.28, 95% CI: 1.06–1.55) in the stage II colon cancer patient group, whereas no significant correlation with disease-free survival was observed in the stage II rectal cancer group. In multivariate analysis both TB and TBR estimates were independent of other clinical parameters (age, gender, total leukocyte count, K-RAS mutational status and MSI). We conclude that miR-21 is primarily a stromal microRNA, which when measured by image analysis identifies a subgroup of stage II colon cancer patients with short disease-free survival
Predicting Diabetic Nephropathy Using a Multifactorial Genetic Model
AIMS: The tendency to develop diabetic nephropathy is, in part, genetically determined, however this genetic risk is largely undefined. In this proof-of-concept study, we tested the hypothesis that combined analysis of multiple genetic variants can improve prediction. METHODS: Based on previous reports, we selected 27 SNPs in 15 genes from metabolic pathways involved in the pathogenesis of diabetic nephropathy and genotyped them in 1274 Ashkenazi or Sephardic Jewish patients with Type 1 or Type 2 diabetes of >10 years duration. A logistic regression model was built using a backward selection algorithm and SNPs nominally associated with nephropathy in our population. The model was validated by using random "training" (75%) and "test" (25%) subgroups of the original population and by applying the model to an independent dataset of 848 Ashkenazi patients. RESULTS: The logistic model based on 5 SNPs in 5 genes (HSPG2, NOS3, ADIPOR2, AGER, and CCL5) and 5 conventional variables (age, sex, ethnicity, diabetes type and duration), and allowing for all possible two-way interactions, predicted nephropathy in our initial population (C-statistic = 0.672) better than a model based on conventional variables only (C = 0.569). In the independent replication dataset, although the C-statistic of the genetic model decreased (0.576), it remained highly associated with diabetic nephropathy (χ(2) = 17.79, p<0.0001). In the replication dataset, the model based on conventional variables only was not associated with nephropathy (χ(2) = 3.2673, p = 0.07). CONCLUSION: In this proof-of-concept study, we developed and validated a genetic model in the Ashkenazi/Sephardic population predicting nephropathy more effectively than a similarly constructed non-genetic model. Further testing is required to determine if this modeling approach, using an optimally selected panel of genetic markers, can provide clinically useful prediction and if generic models can be developed for use across multiple ethnic groups or if population-specific models are required
Genome-Wide Association Scan for Diabetic Nephropathy Susceptibility Genes in Type 1 Diabetes
10.2337/db08-1514Diabetes5861403-1410DIAE
EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours
Missense mutations in TP53 gene promote metastasis in human tumours. However, little is known about the complete loss of function of p53 in tumour metastasis. Here we show that squamous cell carcinomas generated by the specific ablation of Trp53 gene in mouse epidermis are highly metastatic. Biochemical and genome-wide mRNA and miRNA analyses demonstrated that metastases are associated with the early induction of epithelial-mesenchymal transition (EMT) and deregulated miRNA expression in primary tumours. Increased expression of miR-21 was observed in undifferentiated, prometastatic mouse tumours and in human tumours characterized by p53 mutations and distant metastasis. The augmented expression of miR-21, mediated by active mTOR and Stat3 signalling, conferred increased invasive properties to mouse keratinocytes in vitro and in vivo, whereas blockade of miR-21 in a metastatic spindle cell line inhibits metastasis development. Collectively these data identify novel molecular mechanisms leading to metastasis in vivo originated by p53 loss in epithelia
- …